Clinical trials
Rhinitis, Allergic trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Active, not recruiting | 4 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 8 |
| Queen's University | 4 |
| Dr. Anne Ellis | 3 |
| Regeneron Pharmaceuticals | 3 |
| University of British Columbia | 3 |
| Bayer | 2 |
| HAL Allergy | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Lakehead University | 2 |
| Laval University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rhinitis, Allergic | 48 |
| Asthma | 7 |
| Rhinitis, Allergic, Seasonal | 7 |
| Hypersensitivity | 6 |
| Rhinitis | 6 |
| Rhinitis, Allergic, Perennial | 6 |
| Conjunctivitis | 3 |
| Conjunctivitis, Allergic | 2 |
| Food Hypersensitivity | 2 |
| Dermatitis | 1 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.